Completed PHASE2 INTERVENTIONAL NCT00042588

A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

Sponsor: ICOS Corporation

Conditions Pneumonia Sepsis

Interventions Recombinant Chimeric Monoclonal Antibody

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: May 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pneumonia and Sepsis and is currently completed. ICOS Corporation leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ICOS Corporation

Data source: ICOS Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bothell, United States